Vascular adrenoceptors: An update

Pharmacological Reviews

Volumn 53, Issue 2, 2001, Pages 319-356

  Guimarães, Serafim ^a,b   Moura, Daniel ^a  

^a Inst of Pharmacol and Therapeutics   (Portugal)

^b Institute of Pharmacology and Therapeutics   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR; CATECHOLAMINE; NORADRENALIN; RECEPTOR SUBTYPE;

ADRENERGIC SYSTEM; AMYLOID NEUROPATHY; BLOOD PRESSURE REGULATION; CAPACITANCE BLOOD VESSEL; CARDIOVASCULAR SYSTEM; CATECHOLAMINE RELEASE; HYPERTENSION; NEUROTRANSMITTER RELEASE; PARKINSON DISEASE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROTEIN CONFORMATION; PROTEIN LOCALIZATION; RAYNAUD PHENOMENON; REVIEW; SCLERODERMA; SHY DRAGER SYNDROME; SYMPATHETIC NERVE; VASCULAR ENDOTHELIUM; VASCULAR RESISTANCE;

ANIMALS; ENDOTHELIUM, VASCULAR; HUMANS; MUSCLE, SMOOTH, VASCULAR; RECEPTORS, ADRENERGIC, ALPHA; RECEPTORS, ADRENERGIC, BETA; SPECIES SPECIFICITY; SYMPATHETIC NERVOUS SYSTEM; VASODILATION;

EID: 0034999544     PISSN: 00316997     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (524)

1. 1-adrenoceptor mediating contraction of rat aorta, vas deferens and spleen. Br J Pharmacol 109:80-87.
2. 3H-noradrenaline release from rabbit isolated aorta. Naunyn-Schmiedeberg's Arch Pharmacol 339:281-287.
3. 3H-noradrenaline release from rabbit isolated ear artery. Naunyn-Schmiedeberg's Arch Pharmacol 343:161-165.
4. Adler-Graschinsky E and Langer SZ (1975) Possible role of a β-adrenoceptor in the regulation of noradrenaline release by nerve stimulation through a positive feedback mechanism. Br J Pharmacol 53:43-50.
5. Ahlquist RF (1948) A study of the adrenotropic receptors. Am J Physiol 153:586-600.
6. 2-adrenoceptors. Br J Pharmacol 88:607-615.
7. Alexander SPH and Peters JA (1999) Receptor and Ion Channel Nomenclature Supplement, 10th ed, Trends in Pharmacological Sciences, Cambridge, UK.
8. 2A-adrenergic receptor knockout mice. Mol Pharmacol 56:154-161.
9. Altura BM (1971) Chemical and humoral regulation of blood flow through the precapillary sphincter. Microvasc Res 3:361-384.
10. Andrade C (1952) A peculiar form of peripheral neuropathy: familial atypical generalized amyloidosis with special involvement of peripheral nerves. Brain 75:408-427.
11. Angus JA, Cocks TM and Satoh K (1986) The α-adrenoceptors on endothelial cells. Fed Proc 45:2355-2359.
12. Apparsundaram S and Eikenburg DC (1995) Role of prejunctional beta-adrenoceptors in rat cardiac sympathetic neurotransmission. J Pharmacol Exp Ther 272:519-526.
13. 4"-adrenoceptors. Pharmacol Toxicol 83:40-41.
14. Arch S Jr, Ainsworth AT, Cawthorne MA, Piercy V, Sennit MV, Thody VE, Wilson C and Wilson S (1984) Atypical β-adrenoceptor on brown adipocytes as target for anti-obesity drugs. Nature (Lond) 309:163-165.
15. Arch S Jr and Kaumann AJ (1993) Beta 3 and atypical beta-adrenoceptors. Med Res Rev 13:663-729.
16. 1L-adrenoceptor mediates contraction of canine subcutaneous resistance arteries. J Pharmacol Exp Ther 295:627-633.
17. 3-adrenergic receptor - a cause and a cure of obesity? N Engl J Med 333:382-383.
18. Aronica E, Yankaya D, vanVliet E, Lopes da Silva F and Gorter J (2001) Induction of neonatal channel II and III alpha-isoform mRNAs in neurons and microglia after stautus epilepticus in the rat. Eur J Neurosci 13:1261-1266.
19. Arribas S, Marin J, Ponte A, Balfagon G and Salaices M (1994) Norepinephrine-induced relaxations in aorta mediated by endothelial beta-adrenoceptors. Impairment by aging and hypertension. J Pharmacol Exp Ther 270:520-527.
20. Asano T, Katada T, Gilman AG and Ross EM (1984) Activation of the inhibitory protein of adenylate cyclase, Gi, by beta-adrenergic receptors in reconstituted phospholipid vesicles. J Biol Chem 259:9351-9354.
21. 3-adrenoceptor agonist induces increased pancreatic islet blood flow and insulin secretion in rats. Eur J Pharmacol 298:287-292.
22. Barnes PJ (1995) Beta-adrenergic receptors and their regulation. Am J Respir Crit Care Med 152:838-860.
23. Barrow JC, Nantermet PG, Selnick HG, Glass KL, Rittle KE, Gilbert KF, Steele TG, Homnick CF, Freidinger RM, Ransom RW, Kling P, Reiss D, Broten TP, Schorn TW, Chang RS, O'Malley SS, Olah TV, Ellis JD, Barrish A, Kassahun K, Leppert P, Nagarathnam D and Forray C (2000) In vitro and in vivo evaluation of dihydropyrimidinone C-5 amides as potent and selective alpha (1A) receptor antagonists for the treatment of benign prostatic hyperplasia. J Med Chem 43:2703-2718.
24. Begonha R, Moura D and Guimarães S (1995) Vascular β-adrenoceptor-mediated relaxation and the tone of the tissue in canine arteries. J Pharm Pharmacol 47:510-513.
25. Berlan M, Galitzky J, Bousquet-Melou A, Lafontan M and Montrastruc JL (1994) β-3 adrenoceptor-mediated increase in cutaneous blood flow in the dog. J Pharmacol Exp Ther 268:1444-1451.
26. Berthelsen S and Pettinger WA (1977) A functional basis for classification of α-adrenergic receptors. Life Sci 21:595-606.
27. Bevan JA (1977) Some functional consequences of variation in adrenergic synaptic cleft width and in nerve density and distribution. Fed Proc 36:2439-2443.
28. Bevan JA, Bevan RD and Duckles SP (1980) Adrenergic regulation of vascular smooth muscle, in Handbook of Physiology - Cardiovascular System (Bohr DF, Somlyo AP and Sparks HV eds) pp 515-566, Williams & Wilkins Company, Baltimore.
29. Bevan RD, Dodge J, Nichols P, Penar PL, Walters CL, Wellman T and Bevan JA (1998a) Weakness of sympathetic neural control of human pial compared with superficial temporal arteries reflects low innervation density and poor sympathetic responsiveness. Stroke 29:212-221.
30. Bevan RD, Dodge J, Nichols P, Poseno T, Vijayakumaran E, Weilman T and Bevan JA (1998b) Responsiveness of human infant cerebral arteries to sympathetic nerve stimulation and vasoactive agents. Pediatr Res 44:730-739.
31. Bevan JA, Duckworth J, Laher I, Oriowo MA, McPherson GA and Bevan RD (1987) Sympathetic control of cerebral arteries: specialization in receptor type, reserve, affinity and distribution. FASEB J 1:193-198.
32. Black JW, Crowther AF, Shanks RG, Smith LH and Dornhorst AC (1964) A new adrenergic beta-receptor antagonist. Lancet I:1080-1081.
33. Blankestijn P, Tulen J, Boomsma F, Van Eck HJR, Mulder P, Man in't Veld AJ, Van Den Meiracker AH, Moleman P, Derkx FHM, Lamberts SJ and Schlekamp M (1988) Support for adrenaline-hypertension hypothesis: 18 hour pressor effect after 6 hours adrenaline infusion. Lancet ii:1386-1389.
34. Blaylock NA and Wilson VG (1995) Pharmacological characterization of noradrenaline-induced contractions of the porcine isolated palmer lateral vein and palmar common digital artery. Br J Pharmacol 114:694-702.
35. Bloor BC, Frankland M, Alper G, Raybould D, Weitz J and Shurtliff M (1992) Hemodynamic and sedative effects of dexmedetomidine in dog. J Pharmacol Exp Ther 263:690-697.
36. Blue DR, Bond RA, Adham N, Delmondo R, Michel A, Eglen RM, Whiting RL and Clarke DE (1989) Interaction of dihydroalprenolol and cyanopindolol with atypical β-adrenoceptors in guinea-pig ileum. Br J Pharmacol 96:242P.
37. Bockman CS, Gonzalez-Cabrera I and Abel PW (1996) Alpha-2 adrenoceptor subtype causing nitric oxide-mediated vascular relaxation in rats. J Pharmacol Exp Ther 278:1235-1243.
38. Bockman CS, Jeffries WB and Abel PW (1993) Binding and functional characterization of alpha-2 adrenergic receptor subtypes on pig vascular endothelium. J Pharmacol Exp Ther 267:1126-1133.
39. Bockman CS, Jeffries WB, Pettinger WA and Abel PW (1992) Enhanced release of endothelium-derived relaxing factor in mineralocorticoid hypertension. Hypertension 20:304-313.
40. 1-adrenoceptors. Eur J Pharmacol 172:131-145.
41. Bohr DF (1967) Adrenergic receptors in coronary arteries. Ann NY Acad Sci 139: 799-807.
42. Bojanic D, Jansen JD, Nahorski SR and Zaagsma J (1985) Atypical characterization of the β-adrenoceptor mediating cAMP generation lipolysis in the rat adipocyte. Br J Pharmacol 84:131-137.
43. Borkowski KR (1991) Effect of adrenal demedullation and adrenaline on hypertension development and vascular reactivity in young spontaneously hypertensive rats. J Auton Pharmacol 11:1-14.
44. Borkowski KR, Gross R and Schneider H (1992) Vascular β-adrenoceptor-mediated responses in hypertension and ageing rats. J Auton Pharmacol 12:389-401.
45. Borkowski KR and Quinn P (1985) Adrenaline and the development of spontaneous hypertension in rats. J Auton Pharmacol 5:89-100.
46. Boudreau G, Péronnet F, De Champlain J and Nadeau R (1993) Presynaptic effects of epinephrine on norepinephrine release from cardiac sympathetic nerves in dogs. Am J Physiol 265:H205-H211.
47. Brawley L, MacDonald S and Shaw AM (1998) Role of endothelium in classical and atypical β-adrenoceptor-mediated vasorelaxation in rat isolated aorta. Br J Pharmacol 122:395.
48. 2-and atypical β-adrenoceptor-mediated relaxation in rat isolated aorta. Br J Pharmacol 129:637-644.
49. Brawley L, Shaw AM and MacDonald A (2000b) Role of endothelium/nitric oxide in atrypical β-adrenoceptor-mediated relaxation in rat isolated aorta. Eur J Pharmacol 398:285-296.
50. Brodde O-E, Konschak U, Becker K, Rüter F, Poller U, Jakubetz J and Radke J (1998) Cardiac muscarinic receptors decrease with age. J Clin Invest 101:471-478.
51. Brodde O-E and Michel M (1999) Adrenergic and muscarinic receptors in the human heart. Pharmacol Rev 51:651-689.
52. Brodde O-E and Pönicke K (1998) Age-dependent changes of human cardiac β-adrenoceptors. Pharmacol Toxicol 83:35-36.
53. Brown AM (1990) Regulation of heartbeat by G protein-coupled ion channels. Am J Physiol 259:H1621-H1628.
54. Brown MJ and Macquin I (1981) Is adrenaline the cause of essential hypertension? Lancet ii:1079-1081.
55. Bryan LJ, Cole JJ, O'Donnell SR and Wanstall JC (1981) A study designed to explore the hypothesis that beta-1 adrenoceptors are "innervated" receptors and beta-2 adrenocepors are "hormonal" receptors. J Pharmacol Exp Ther 216:395-400.
56. 2-adrenoceptors. Br J Clin Pharmacol 21:721-722.
57. Bünemann M, Lee KB, Pals-Rylaarsdam R, Roseberry AG and Hosey MM (1999) Desensitization of G-protein-coupled receptors in the cardiovascular system. Ann Rev Physiol 61:169-192.
58. 1B-adrenoceptor mediating contraction of the rat spleen. Br J Pharmacol 115: 467-475.
59. 2+ influx stimulated by diacylglycerol and PKC. Br J Pharmacol 123:317-325.
60. Busse R, Fisslthaler B and Fleming I (1998) Activation of the endothelial nitric oxide synthase by fluid shear stress. Pharmacol Toxicol 83:47-48.
61. Buxton BF, Jones CR, Molenaar P and Summers RJ (1987) Characterization and autoradiographic localization of β-adrenoceptor subtypes in human cardiac tissues. Br J Pharmacol 92:299-310.
62. 2-adrenergic receptors: comparison of pharmacologically defined subtypes with subtypes identified by molecular cloning. Mol Pharmacol 42:1-5.
63. 2 adrenergic receptor subtype in human ocular tissue homogenates. Invest Ophthalmol Vis Sci 40:2299-2308.
64. Bylund DB, Eikenberg DC, Hieble JP, Langer SZ, Lefkowitz JR, Minneman KP, Molinoff PB, Ruffolo RR and Trendelenburg U (1994) IV International Union of Pharmacology Nomenclature of Adrenoceptors. Pharmacol Rev 46:121-136.
65. Bylund DB, Hass NA, Cerutis DR and Blaxall HS (1995a) Characterization of alpha-2 adrenergic receptor subtypes. Pharmacol Commun 6:87-90.
66. 2B Adrenergic receptor subtypes: antagonist binding in tissues and cell lines containing only one receptor subtype. J Pharmacol Exp Ther 245:600-607.
67. Bylund DB, Regan JW, Faber JE, Hieble JP, Triggle CR and Ruffolo RR Jr (1995b) Vascular u-adrenoceptors: from the gene to the human. Can J Physiol Pharmacol 73:533-543.
68. Callingham BA, Carr G and Milton AS (1998) The responses of the digital artery of the follow deer, Dama dama, in a mild winter. J Physiol 511P:2P.
69. 3-adrenergic receptor antagonists. J Pharmacol Exp Ther 290:649-655.
70. Carvalho MJ, Meiracker AH, Boomsma F, Man in't Veld AJ, Freitas J, Costa O and Falcão-de-Freitas A (1997) Improved orthostatic tolerance in familiar amyloidotic polyneuropathy with unnatural noradrenaline precursor L-threo-3,4-dihydroxyphenylserine. J Auton Nerv Syst 62:63-71.
71. 1b-adrenergic receptor. Proc Natl Acad Sci USA 94:11589-11594.
72. Chang PC, Kriek E and van Brummelen P (1994) Sympathetic activity and presynaptic adrenoceptor function in patients with longstanding essential hypertension. J Hypertension 12:179-190.
73. 1A-adrenoceptor isoforms. FEBS Lett 422:279-283.
74. Chapman J, Schutzer W, Watts VJ and Mader SL (1999) Impaired cholera toxin relaxation with age in rat aorta. J Gerontol 54:B154-B159.
75. Chapple CR and Chess-Williams R (1999) Curr Opin CPNS Invest Drugs 1:231-238.
76. Chaudry A, MacKenzie RG, Georgic LM and Granneman JG (1994) Differential interaction of beta (1)- and beta (3)-adrenergic receptors with G (i) in rat adipocytes. Cellular Signalling 6:457-465.
77. Chen L, Xin X, Eckhart AD, Yang N and Faber JE (1995) Regulation of vascular smooth muscle growth by alpha 1-adrenoceptor subtypes in vitro and in situ. J Biol Chem 270:30980-30988.
78. Chen XH, Harden TK and Nicholas RA (1994) Molecular cloning and characterization of a novel beta-adrenergic receptor. J Biol Chem 269:24810-24819.
79. 2C-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries. Am J Physiol 278:H1075-H1083.
80. 2 adrenergic receptor gene. J Biol Chem 274: 16694-16700.
81. Clark BJ and Bertholet A (1983) Effects of pindolol on vascular smooth muscle. Gen Pharmacol 14:117-119.
82. 3-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity. N Engl J Med 333:352-354.
83. Cocks TM and Angus JA (1983) Endothelium-dependent relaxation of coronary arteries by noradrenaline and serotonin. Nature (Lond) 305:627-630.
84. 2 receptor hypersensitivity in Raynaud's phenomenon. J Vasc Med Biol 2:100-106.
85. Cohen RA, Shepherd JT and Vanhoutte PM (1983) 5-Hydroxytryptamine can mediate endothelium-dependent relaxation of coronary arteries. Am J Physiol 245: 1077-1080.
86. Cohen RA, Shepherd JT and Vanhoutte PM (1984) Neurogenic cholinergic prejunctional inhibition of sympathetic beta adrenergic relaxation in the canine coronary artery. J Pharmacol Exp Ther 229:417-421.
87. Conlon D, Johnston A, O'Malley K, Turner P and Kilfeather S (1995) Effect of ageing and propranolol administration on myocardial β-adrenoceptor receptor function in mature rats. Eur J Pharmacol 289:283-290.
88. 2-adrenoceptors. Br J Pharmacol 101:285-290.
89. 1-adrenoceptors in dog saphenous vein exposed to phenoxybenzamine. Eur J Pharmacol 85:325-329.
90. Cooke JP, Shepherd JT and Vanhoutte PM (1984) The effect of warming on adrenergic neurotransmission in canine cutaneous vein. Circ Res 54:547-553.
91. 2-adrenoceptors during swimming exercise. Eur J Pharmacol 274:33-40.
92. 2-adrenoceptors in freely moving rats by adrenaline released as a co-transmitter. Eur J Pharmacol 243:273-279.
93. Cotecchia S, Kobilka BK, Daniel KW, Nolan HD, Lapetina EY, Caron MG, Lefkowitz RJ and Regan JW (1990) Multiple second messenger pathways of α-adrenergic receptor subtypes expressed in eukaryotic cells. J Biol Chem 265:63-69.
94. 1-adrenergic receptor. Proc Natl Acad Sci USA 85:7159-7163.
95. Dahlöf C, Kahan T and Ablad B (1978) Increased noradrenaline release in rat portal vein during sympathetic nerve stimulation due to activation of presynaptic β-adrenoceptors by noradrenaline and adrenaline. Eur J Pharmacol 50:75-78.
96. Dainty IA, McGrath JC, Spedding M and Templeton Agb (1990) The influence of the initial stretch and the agonist-induced tone on the effect of basal and stimulated release of EDRF. Br J Pharmacol 100:767-773.
97. Dale HH (1905) On some physiological actions of ergot. J Physiol 34:163-206.
98. Daniel EE, Brown RD, Wang YF, Low AM, Lu-Chao H and Kwan CY (1999) α-Adrenoceptors in canine mesenteric artery are predominantly 1A-subtype: pharmacological and immunochemical evidence. J Pharmacol Exp Ther 291:671-679.
99. 2-adrenoceptors and other adrenoceptors in membranes isolated from dog mesenteric nerve axons. J Pharmacol Exp Ther 275:978-986.
100. Davis BJ, Noble A, Chapple CR and Chess-Williams R (2000) Human prostate-artery selectivity of tamsulosin, doxazosin and alfuzosin. Br J Pharmacol 129:52P.
101. 2-adrenergic system of the platelet. Clin Sci 73:507-513.
102. Dawes M, Chowienczyk PJ and Ritter JM (1997) Effects of inhibition of the L-arginine/nitric oxide pathway on vasodilation caused by β-adrenergic agonists in human forearm. Circulation 95:2293-2297.
103. 2+ channels in rat sympathetic neurons. J Physiol 518:23-36.
104. Delpy E, Coste H, Le Monnier De and Gouville A-C (1996) Effects of cyclic GMP elevation on isoprenaline-induced increase in cyclic AMP and relaxation in rat aortic smooth muscle: role of phosphodiesterase 3. Br J Pharmacol 119:471-478.
105. 1- and alphas-like adrenoceptors in canine arterial and venous smooth muscle. Circ Res 48:875-884.
106. 3-adrenoceptor antagonist SR 59,230. Br J Pharmacol 117:1374-1376.
107. DeQuattro VL and Chan S (1972) Raised plasma catecholamines in some patients with primary hypertension. Lancet 1:806-809.
108. Desai KH, Sato R, Schauble E, Barsh GS, Kobilka BK and Bernstein D (1997) Cardiovascular indexes in the mouse at rest and with exercise: new tools to study models of cardiac disease. Am J Physiol 272:H1053-H1061.
109. Dixon RA, Kobilka BK, Strader DJ, Benovic JL, Dohlman HG, Frielle T, Bolanowski MA, Bennett CD, Rands E, Diehl RE, Mumford RA, Slater EE, Sigal IS, Caron MG, Lefkowitz RJ and Strader CD (1986) Cloning of the gene and cDNA for mammalian beta-adrenergic receptor and homology with rhodopsin. Nature (Lond) 321: 75-79.
110. Docherty JR (1990) Cardiovascular responses in ageing: a review. Pharmacol Rev 42:103-125.
111. 2-adrenoceptors. Eur J Pharmacol 361:1-15.
112. Docherty JR and Starke K (1981) Postsynaptic u-adrenoceptor subtypes mediating nerve-evoked contractions in rabbit blood vessels in vitro. Br J Pharmacol 74: 803P.
113. Doggrell SA (1990) Relaxant and beta 2-adrenoceptor blocking activities of (±)-, (±)- and (-)-pindolol on the rat isolated aorta. J Pharm Pharmacol 42:444-446.
114. Dohi Y, Kojima M, Sato K and Luscher TF (1995) Age-related changes in vascular smooth muscle and endothelium. Drugs Aging 7:278-291.
115. Donoso AO and Barontini M (1986) Increase in plasma catecholamines by intraventricular injection of histamine. Naunyn-Schmiedeberg's Arch Pharmacol 334:188-192.
116. Dubocovich ML and Langer SZ (1974) Negative feedback regulation of noradrenaline release by nerve stimulation in the perfused cat's spleen: differences in potency of phenoxybenzamine in blocking the pre- and post-synaptic receptors. J Physiol 237:505-519.
117. 3-adrenoceptor antagonist, SR 59230A. Eur J Pharmacol 348:223-228.
118. 1 and β-adrenoceptors in rabbit heart in relation to sympathetic nerve endings. Eur J Pharmacol 381:135-140.
119. Eason MG and Liggett SB (1992) Subtype selective desensitization of alpha-2-adrenergic receptors. Different mechanisms control short and long-term agonist-promoted desensitization of alpha 2C10, alpha 2C4, and alpha 2C2. J Biol Chem 267:25473-25479.
120. Eckly AE, Stoclet J-C and Lugnier C (1994) Isoprenaline induces endothelium-independent relaxation and accumulation of cyclic nucleotides in the rat aorta. Eur J Pharmacol 271:237-240.
121. Edvinsson L and Owman C (1974) Pharmacological characterization of adrenergic alpha and beta receptors mediating the vasomotor responses of cerebral arteries in vitro. Circ Res 35:835-849.
122. Egleme C, Godfraind T and Miller RC (1984) Enhanced responsiveness of isolated rat aorta to clonidine after removal of the endothelial cells. Br J Pharmacol 81:16-18.
123. 3-adrenergic receptor. Science (Wash DC) 245:1118-1121.
124. Encabo A, Ferrer M, Salaices M, Manso R, Marin J and Balfagon G (1996) Effect of clenbuterol on the modulation of noradrenaline release in the rat tail artery. J Auton Pharmacol 16:243-256.
125. 125Iodo)cyanopindolol, a new ligand for β-adrenoceptors: identification and quantification of subclasses of β-adrenoceptors in guinea pig. Naunyn-Schmiedeberg's Arch Pharmacol 317:277-285.
126. Engleman K and Portnoy B (1970) A sensitive double-isotope derivative assay for norepinephrine and epinephrine. Circ Res 26:53-57.
127. 2-adrenoceptors which modulate noradrenaline release in rabbits and rat occipital cortex. Br J Pharmacol 85:318P.
128. Fagura MS, Lydford SJ and Dougall IG (1997) Pharmacological classification of alpha 1-adrenoceptors mediating contractions of rabbit isolated ear artery: comparison with rat isolated thoracic aorta. Br J Pharmacol 120:247-258.
129. Falcão-de-Freitas A (1996) Treatment of orthostatic hypotension with L-threo-DOPS in familial amyloidotic polyneuropathy. Amyloid: Int J Exp Clin Invest 3:212-213.
130. 1-adrenoceptor subtypes present in the human prostate. Life Sci 54:1595-1605.
131. 2-adrenoceptors in human umbilical vein endothelium in vitro. Br J Pharmacol 126:1872-1880.
132. 3-adrenergic receptor agonist increases metabolic rate in Rhesus monkeys. J Clin Invest 101:2387-2393.
133. Flavahan NA, Cooke JP Shepherd JT and Vanhoutte PM (1987a) Human postjunctional alpha-1 and alpha-2 adrenocepors: differential distribution in arteries of the limbs. J Pharmacol Exp Ther 241:361-365.
134. 2-adrenergic constriction of isolated arterioles in diffuse scleroderma. Arthritis Rheum 43:1886-1890.
135. Flavahan NA, Miller VM, Aarhus LL and Vanhoutte PM (1987b) Denervation augments alpha-2 but not alpha-1 adrenergic responses in canine saphenous veins. J Pharmacol Exp Ther 240:589-593.
136. Flavahan NA, Rimele TJ, Cooke JP and Vanhoutte PM (1984) Characterization of alpha-1 and alpha-2 adrenoceptors activated by exogenous or nerve-released norepinephrine in the canine saphenous vein. J Pharmacol Exp Ther 230:699-705.
137. 1-Adrenoceptor subclassification in vascular smooth muscle. Trends Pharmacol Sci 7:347-349.
138. Flavahan N and Vanhoutte PM (1986b) Effect of cooling on alpha-1 and alpha-2 adrenergic responses in canine saphenous and femoral veins. J Pharmacol Exp Ther 238:139-147.
139. Floras JS (1992) Epinephrine and the genesis of hypertension. Hypertension 19:1-18.
140. Floras JS, Aylward PE, Victor RG, Mark AL and Abboud FM (1988) Epinephrine facilitates neurogenic vasoconstriction in humans. J Clin Invest 81:1265-1274.
141. Foglar R, Shibata K, Hone K, Hirasawa A and Tsujimoto G (1995) Use of recombinant alpha 1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur J Pharmacol 288:201-207.
142. Folkow B (1982) Physiological aspects of primary hypertension. Physiol Rev 62:347-504.
143. 1-adrenoceptors in human prostate: implications for adrenoceptor classification. Mol Pharmacol 49:209-215.
144. Ford APDW, Chang DJ, Clarke DE, Daniels DV, Eglen RM, Gever JR, Jasper JR, Kava MS, Lachnit WG, Lesnick JD, Melov TD, Stepan GT and Williams TJ (1998) Alpha-1A-versus alpha-1L-adrenoceptors: a pharmacological comparison. Pharmacol Toxicol 83:12-15.
145. 1-adrenoceptor classification. Br J Pharmacol 121: 1127-1135.
146. 1-Adrenoceptor classification: sharpening Occam's razor. Trends Pharmacol Sci 15:167-170.
147. 3-adrenoceptor agonist; in vitro pharmacology and profile of activity in vivo in the rhesus monkey Eur J Pharmacol 407:175-181.
148. Fouda A-K and Atkinson J (1986) Sensitivity to noradrenaline and electrical stimulation decreases with age in the rat tail artery. Naunyn-Schmiedeberg's Arch Pharmacol 344:37-39.
149. Freedman RR, Baer RP and Mayes MD (1995) Blockade of vasospastic attacks by alpha2-adrenergic but not alphal-adrenergic antagonist in idiopathic Raynaud's disease. Circulation 92:1448-1451.
150. Freedman RR, Girgis R and Mayes MD (1999) Endothelial and adrenergic dysfunction in Raynaud's phenomenon and scleroderma. J Rheumatol 26:2386-2388.
151. Freedman RR, Moten M, Migaly P and Mayes M (1993) Cold-induced potentiation of alpha 2-adrenergic vasoconstriction in primary Raynaud's disease. Arthritis Rheum 36:685-690.
152. Freissmuth M, Waldhoer M, Bofill-Cardona E and Nanoff C (1999) G protein antagonists. Trends Pharmacol Sci 20:237-245.
153. Frielle T, Collins S, Daniel KW, Caron MG, Lefkowitz RJ and Kobilka BK (1987) Cloning of the cDNA for the human beta 1-adrenergic receptor. Proc Natl Acad Sci USA 84:7920-7924.
154. 2 of yohimbine and phentolamine on the perfused rat heart under conditions of negligible autoinhibition. Br J Pharmacol 79:109-119.
155. Fujisawa T, Ikegami H, Yamato E, Hamada Y, Kamide K, Rakugi H, Higaki J, Murakami H, Shimamoto K and Ogihara T (1997) Trp64Arg mutation of beta3 adrenergic receptor in essential hypertension: insulin resistance and the adrenergic system. Am J Hypertens 10:101-105.
156. Furchgott RF (1967) The pharmacological differentiation of adrenergic receptors. Ann N Y Acad Sci 139:553-570.
157. Furchgott RF (1972) The classification of adrenoceptors (adrenergic receptors). An evaluation from the standpoint of receptor theory, in Catecholamines, Handbook of Experimental Pharmacology XXXIII (Blaschko H and Muscholl E eds) pp 283-335, Springer, Berlin.
158. Furchgott RF and Zawadzki JV (1980) The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature (Lond) 288:373-376.
159. Furuta T, Ishikawa N and Shigei T (1986) Regional variation in β-adrenoceptor-mediated relaxation of canine veins. Blood Vessels 23:236-245.
160. Galitzky J, Langin D, Montrastruc J-L, Lafontan M and Berlan M (1998) On the presence of a putative fourth β-adrenoceptor in human adipose tissue. Trends Pharmacol Sci 19:164-165.
161. Gao Y, Tolsa JF, Botello M and Raj JU (1998) Developmental change in isoproterenol-mediated relaxation of pulmonary veins of fetal and newborn lambs. J Appl Physiol 84:1535-1539.
162. 1-Adrenoceptors function and phosphorylation. Eur J Pharmacol 389:1-12.
163. G-nitro-L-arginine methyl ester on vasodilator responses to acetylcholine, 5′-N-ethytcarboxamidoadenosine or salbutamol in conscious rats. Br J Pharmacol 103:1725-1732.
164. 3-Adrenoceptors in the cardiovascular system. Trends Pharmacol Sci 21:426-431.
165. Gauthier C, Tavernier G, Charpentier F, Langin D and Lemarec H (1996) Functional beta (3)-adrenoceptor in the human heart. J Clin Invest 98:556-562.
166. 2C-Adrenoceptors mediate contractile responses to noradrenaline in human saphenous vein. Naunyn-Schmiedeberg's Arch Pharmacol 355:406-411.
167. Giannuzzi CE, Seidler FJ and Slotkin TA (1995) Beta-adrenoceptor control of cardiac adenylyl cyclase during development: agonist pretreatment in the neonate uniquely causes sensitization, not desensitization. Brain Res 694:271-278.
168. 1D-adrenoceptors in rat aorta. J Pharmacol Exp Ther 295:810-817.
169. Goldstein DS, Golczynska A, Stuhlmuller J, Holmes J, Rea RF, Grossman E and Lenders J (1999) A test of the "epinephrine hypothesis" in humans. Hypertension 33:36-43.
170. Goldstein DS, Holmes C, Sheng-Ting L, Bruce S, Metman LV and Cannon RO (2000) Cardiac sympathetic denervation in Parkinson disease. Ann Intern Med 133:338-347.
171. 2-adrenoceptors. J Pharm Pharmacol 41:52-54.
172. Goodman OB, Krupnick JG, Santini F, Gurevich W, Penn RB, Gagnon AW, Keen JH and Benovic JL (1996) β-Arrestin acts as a clathrin adaptor in endocytosis of the β-adrenergic receptor. Nature (Lond) 383:447-450.
173. 2-adrenoceptors on the sympathetic nerve fibres of the human pulmonary artery. Br J Pharmacol 85:933-941.
174. Grace GC, MacDonald PS and Dusting GJ (1988) Cyclic nucleotide interactions involved in endothelium-dependent dilatation in rat aortic rings. Eur J Pharmacol 148:17-24.
175. 3-adrenergic receptor messenger ribonucleic-acids. Endocrinology 135:1025-1031.
176. 3-adrenoceptor agonist. Br J Pharmacol 112:213P.
177. Gray DW and Marshall I (1992) Novel signal transduction pathway mediating endothelium-dependent β-adrenoceptor vasorelaxation in rat thoracic aorta. Br J Pharmacol 107:684-690.
178. 1-adrenoceptor. Eur J Pharmacol 151:333-335.
179. 1-adrenenergic receptors. Cell Signal 8:323-333.
180. Guimarães S (1975) Further study of the adrenoceptors of the saphenous vein of the dog: influence of factors which interfere with the concentrations of agonists at the receptor level. Eur J Pharmacol 34:9-19.
181. Guimarães S (1982) Two adrenergic biophases in blood vessels. Trends Pharmacol Sei 3:159-161.
182. Guimarães S (1986) Postsynaptic α-adrenoceptors in blood vessels: discrepancies between results obtained in vivo and in vitro, in New Aspects of the Role of Adrenoceptors in the Cardiovascular System (Grobecker H, Philippu A, Starke K eds) pp 129-138, Springer-Verlag, Berlin.
183. Guimarães S (1999) Important recent advances in cardiovascular adrenergic mechanisms. Ann Rev Biol Sci 1:31-58.
184. Guimarães S, Brandão F and Paiva MQ (1978) A study of the adrenoceptor-mediated feedback mechanisms by using adrenaline as a false transmitter. Naunyn-Schmiedeberg's Arch Pharmacol 305:185-188.
185. 2A-autoreceptors in the human gastric and ileocolic arteries. Naunyn-Schmiedeberg's Arch Pharmacol 358:207-211.
186. Guimarães S, Mota A and Begonha R (1993) The effectiveness of β-adrenoceptor stimulation and the contribution of β-adrenoceptors increase from the proximal to the distal part of the canine saphenous vein. Naunyn-Schmiedeberg's Arch Pharmacol 347:596-800.
187. Guimarães S, Moura D, Paiva MQ and Vaz-da-Silva MJ (1994) Lack of postjunctional beta adrenoceptor-mediated effects in the canine saphenous vein at birth. J Pharmacol Exp Ther 268:990-995.
188. 2-adrenoceptor activation increases from the distal to the proximal part of the veins of the canine limbs. Br J Pharmacol 101:387-393.
189. Guimarães S and Paiva MQ (1981a) Two distinct adrenoceptor-biophases in the vasculature: one for α- and the other for β-agonists. Naunyn-Schmiedeberg's Arch Pharmacol 316:195-199.
190. Guimarães S and Paiva MQ (1981b) Two different biophases for adrenaline. Naunyn-Schmiedeberg's Arch Pharmacol 316:200-204.
191. Guimarães S and Paiva MQ (1981c) Are β-agonists able to occupy β-adrenoceptors without causing effect? A study on the saphenous vein of the dog. Proceedings of the 4th Meeting on Adrenergic Mechanisms, pp 37, Porto, Portugal.
192. Guimarães S, Paiva MQ and Moura D (1982) Evidence for the existence of distinct biophases for α- and β-adrenoceptors in the vascular tissue. J Cardiovasc Pharnacol 4:S58-S62.
193. 1-adrenoceptors. Naunyn-Schmiedeberg's Arch Pharmacol 335:397-402.
194. Guimarães S, Paiva MQ, Moura D and Vaz-da-Silva MJ (1991) Presynaptic α-autoadrenoceptors on peripheral noradrenergic neurones of newborn rabbits and dogs, in Advances in the Biosciences Presynaptic Receptors and Neuronal Transporters (Langer SZ, Galzin AM and Costentin J eds) vol 82, pp 11-14, Pergamon Press, Oxford.
195. Guimarães S, Paiva MQ and Pereira O (1997) α-Adrenoceptor-mediated prejunctional effects of chloroethyldonidine in the canine saphenous vein. J Pharmacol Exp Ther 282:1326-1330.
196. 2-adrenoceptors of the dog saphenous vein and their relation to the sympathetic nerve terminals. Prog Neuropsychopharmacol Biol Psych 155.
197. 1-Adrenoceptor responsiveness in aging aorta. Eur J Pharmacol 274:117-123.
198. Gurdal H, Seasholtz TM, Wang HY, Brown RD, Johnson MD and Friedman E (1997) Role of G alpha q or G alpha o proteins in alpha 1-adrenoceptor subtype-mediated responses in Fischer 344 rat aorta. Mol Pharmacol 52:1064-1070.
199. 1-adrenoceptor subtypes changes with age in the rat aorta. J Pharmacol Exp Ther 275:1656-1662.
200. 1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery. Br J Pharmacol 113: 723-728.
201. Hamilton CA and Reid JL (1981) The effect of 6-hydroxydopamine on rabbit peripheral alpha adrenoceptors in vivo and in vitro. Br J Pharmacol 72:119P.
202. 1-adrenergic receptors revealed by chloroethylclonidine. Mol Pharmacol 32:505-510.
203. 1-adrenoceptors in rat blood vessels. Eur J Pharmacol 190:97-104.
204. 1-adrenoceptor recognition sites by urapidil derivatives and other selective antagonists. Br J Pharmacol 97:691-700.
205. 2 adrenergic receptor functional coupling to G proteins in rat brain during postnatal development. J Pharmacol Exp Ther 288:1134-1142.
206. Harker CT, Bowman CJ, Taylor LM and Porter JM (1994) Cooling augments human saphenous vein reactivity to electrical stimulation. J Cardiovasc Pharmacol 23: 453-457.
207. Harms HH, Zaagsma J and Van der Wal B (1974) β-Adrenoceptor studies. III. On the β-adrenoceptors in rat adipose tissue. Eur J Pharmacol 25:87-91.
208. Heck DA and Bylund DB (1998) Differential down-regulation of alpha-2 adrenergic receptor subtypes. Life Sci 62:1467-1472.
209. 2-adrenergic receptors. Novel insight from transgenic animal models, in Clinical Pharmacology. Prediction of Drug Actions from In Vitro Approaches. Fact or Fiction? (Kuhlmann J, Roden DM eds) pp 25-29, W Zuckschwerdt Verlag, Munich.
210. 2-adrenergic receptor subtype function. Rev Physiol Biochem Pharmacol 142:161-185.
211. 2-adrenergic receptors regulate sympathetic neurotransmission. Nature (Lond) 402:181-184.
212. 1B-adrenoceptors. Naunyn-Schmiedeberg's Arch Pharmacol 363:34-39.
213. Hein L and Kobilka BK (1995) Adrenergic receptor signal transduction and regulation. Neuropharmacology 34:357-366.
214. Hein L, Spindler M, Altman JD and Kobilka BK (1998) Alpha-2-adrenoceptor subtypes: distribution and function. Pharmacol Toxicol 83:26-28.
215. Hicks PE, Barras M, Herman G, Maudit P, Armstrong JM and Rossignol B (1991) α-Adrenoceptor subtypes in dog saphenous vein that mediate contraction and inositol phosphate formation. Br J Pharmacol 102:151-161.
216. 1-adrenoceptors: consensus update. Pharmacol Rev 47:267-270.
217. 2-Adrenergic Receptors: Structure, Function and Therapeutic Imputations (Lanier SM, Limbird LE eds) pp 1-18, Harwood, Amsterdam.
218. Hiraoka Y, Taniguchi T, Oshita M and Muramatsu I (2000) Pharmacological analysis of neurogenic, sympathetic mediated through alpha-1-, alpha-2-adrenergic and purinergic receptors in the dog saphenous vein. Pharmacology 60:188-194.
219. 1C-adrenoceptor splice variants. FEBS Lett 363: 256-260.
220. 2-adrenoceptor mediating prejunctional inhibition in rat atrium and cerebral cortex. Naunyn-Schmiedeberg's Arch Pharmacol 357:634-639.
221. Hoefke W and Kobinger W (1966) Pharmakologische Wirkungen des 2-(2,6-dichlorphenylamino)-2-imidazolin-hydrochloride, einer neuen, antihypertensiven substanz. Arzneim-Forsch 16:1038-1050.
222. Hoffman BB and Lefkowitz RJ (1995) Catecholamines, sympathomimetic drugs and adrenergic receptor antagonists, in Goodman & Gilman: The Pharmacological Basis of Therapeutics (Hardman JG, Limbird LE, Molinoff PB, Ruddon RW and Gilman AG eds) 9th ed, pp 199-248, McGraw-Hill, New York.
223. Holck MI, Jones CHM and Haeusler G (1983) Differential interactions of clonidine and methoxamine with the postsynaptic α-adrenoceptor of rabbit main pulmonary artery. J Cardiovasc Pharmacol 5:240-248.
224. 1-adrenoceptors on vascular smooth muscle; correlation with the regulation of contraction. J Pharmacol Exp Ther 290:452-463.
225. 1-adrenoceptor subtypes mediating contractions to phenylephrine in rat thoracic aorta, mesenteric artery and pulmonary artery. Br J Pharmacol 122:849-858.
226. 1-Adrenoceptor subtypes mediating contractions of the rat mesenteric arteries. Eur J Pharmacol 395:69-76.
227. 3-adrenoceptor knock-out mice. Eur J Pharmacol 132:433-442.
228. 1- and β-adrenoceptor-mediated responsiveness of rat aorta. Naunyn-Schmiedeberg's Arch Pharmacol 335:50-53.
229. 1D-adrenoceptors in arteries of normotensive and spontaneously hypertensive rats. Pharmacol Rev Comm 10:135-142.
230. 1A-adrenoceptors in contraction. Br J Pharmacol 129:653-660.
231. 1D-adrenoceptors in the rat vasculature. Eur J Pharmacol 322:221-224.
232. Ignarro LJ, Buga GM, Wood KS, Byrns RE and Chaudhuri G (1987) Endothelium-derived relaxing factor (EDRF) produced and releases from artery and vein is nitric oxide. Proc Natl Acad Sci USA 84:9265-9269.
233. Innes IR and Nickerson M (1970) Drugs acting on postganglionic adrenergic nerve endings and structures innervated by them (sympathomimetic drugs), in Goodman & Gilman: The Pharmacological Basis of Therapeutics (Goodman LS and Gilman A eds) 4th ed, pp 478-523; The MacMillan Co, London.
234. Insel PA (1996) Adrenergic receptors-evolving concepts and clinical implications. N Engl J Med 334:580-585.
235. Iranami H, Hatano Y, Tsukiyama Y, Maeda H and Mizumoto K (1996) A beta-adrenoceptor agonist evokes a nitric oxide-cGMP relaxation mechanism modulated by adenylyl cyclase in rat aorta. Anesthesiology 85:1129-1138.
236. 2+ channel modulation in sympathetic neurons. Proc Natl Acad Sci USA 97:907-912.
237. Jones TR, Charette L, Garcia ML and Kaczorowski GJ (1993) Interaction of iberiotoxin with beta-adrenoceptor agonists and sodium nitroprusside on guinea pig trachea. J Appl Physiol 74:1879-1884.
238. 2-adrenergic receptors. J Pharmacol Exp Ther 293: 1-7.
239. Kahaleh MB (1990) Vascular disease in scleroderma: endothelial T lymphocyte-fibroblast interactions. Rheum Dis Clin North Am 16:53-73.
240. 2-adrenoceptor agonist, on hemodynamic control mechanisms. Clin Pharmacol Ther 46:33-42.
241. Kalsner S (1982) The presynaptic receptor controversy. Trends Pharmacol Sci 3:11-16.
242. Kalsner S and Westfall TC (1990) Presynaptic receptors and the question of autoregulation of transmitter release. Ann NY Acad Sci 604:23-29.
243. Kamata K, Miyata N and Kasuya Y (1989) Involvement of endothelial cells in relaxation and contraction responses of the aorta to isoproterenol in naive and streptozotocin-induced diabetic rats. J Pharmacol Exp Ther 249:890-894.
244. Kanagy NL and Webb RC (1996) Increased responsiveness and decreased expression of proteins in deoxycorticosterone hypertension. Hypertension 27:740-745.
245. Kaumann AJ (1997) Four β-adrenoceptor subtypes in mammalian heart. Trends Pharmacol Sci 18:70-76.
246. 4-adrenoceptor pharmacology. Naunyn-Schmiedeberg's Arch Pharmacol 363:87-93.
247. 2-adrenoceptors in the stimulation of adenylate cyclase and contractile force. Eur Heart J 10:29-37.
248. 3-adrenoceptor in the rat. Br J Pharmacol 118:2085-2098.
249. Kaumann AJ and Molenaar P (1997) Modulation of human cardiac function through 4β-adrenoceptor populations. Naunyn-Schmiedeberg's Arch Pharmacol 355:667-681.
250. 3-adrenoceptor knockout mice. Mol Pharmacol 53:670-675.
251. 1L-Adrenoceptor mediation for lower urinary tract tissues of man. Br J Pharmacol 123:1359-1366.
252. Kenakin T (1997) Preface, in Pharmacologic Analysis of Drug-Receptor Interaction (Kenakin T ed) 3rd ed, pp xiii, Lippincott-Raven, Philadelphia.
253. 1D-adrenoceptor mediating the contractile response of rat aorta to noradrenaline. Br J Pharmacoi 115:981-986.
254. 4-adrenoceptor mediated response occur in parallel in a rat model of cardiac failure. Mol Pharmacol 57:252-258.
255. 1-adrenoceptor subtypes in the mesenteric vasculature of the rat. J Pharmacol Exp Ther 268:1153-1159.
256. Konishi M and Su C (1983) Role of endothelium in dilator response of spontaneously hypertensive rat arteries. Hypertension 5:881-886.
257. 3-adrenergic-independent effects of Cgp 12177 in brown tissue. Mol Pharmacol 57:252-258.
258. 1-adrenergic receptors. J Pharmacol Exp Ther 294:923-932.
259. Krauss SL, Dodge JT and Bevan JA (1992) Magnitude of β-adrenoceptor-mediated responses of dog epicardial arteries: inverse relation to diameter. Am J Physiol 263:H1422-H1429.
260. ++ elevation in Chinese hamster ovary cells. J Pharmacol Exp Ther 287:667-671.
261. Küng CF and Lüscher TF (1995) Different mechanisms of endothelial dysfunction with aging and hypertension in rat aorta. Hypertension 25:194-200.
262. 2-adrenergic receptor subtypes. J Biol Chem 269:10093-10099.
263. 1A-adrenoceptor mediating contractile responses to noradrenaline in isolated caudal artery of rat. Br J Pharmacol 120:819-826.
264. Lands AM, Arnold A, McAuliff JP, Luduena FP and Brown TG Jr (1967a) Differentiation of receptor systems activated by sympathomimetic amines. Nature (Lond) 214:597-598.
265. Lands AM, Luduena FP and Buzzo HJ (1967b) Differentiation of receptors responsive to isoproterenol. Life Sci 6:2241-2249.
266. Langer SZ (1974) Presynaptic regulation of catecholamine release. Biochem Pharmacol 23:1793-1800.
267. Langer SZ (1981) Presynaptic regulation of the release of catecholamines. Pharmacol Rev 32:337-362.
268. Langer SZ (1997) 25 years since the discovery of presynaptic receptors: present knowledge and future perspectives. Trends Pharmacol Sci 18:95-99.
269. 2-adrenoceptors in dog vascular smooth muscle. Br J Pharmacol 72:123P.
270. Langin D, Portillo MP, Saulnier-Blache J-S and Lafontan M (1991) Coexistence of three β-adrenoceptor subtypes in white fat cells of various mammalian species. Eur J Pharmacol 199:291-301.
271. Latifpour J and Bylund DB (1983) Characterization of adrenergic receptor binding in rat lung: physiological regulation. J Pharmacol Exper Ther 224:186-192.
272. 2-adrenergic receptors in neonatal rat lung. J Pharmacol Exp Ther 223:606-611.
273. 2-adrenoceptor antagonists when compared on isolated vasa deferentia of rat and rabbit. Naunyn-Schmiedeberg's Arch Pharmacol 329:278-281.
274. 1B-adrenergic receptor. J Biol Chem 269:22887-22893.
275. Lavoie JL, Trudeau F and Béliveau L (2000) Effect of blood flow and muscle contraction on noradrenaline spillover in the canine gracilis muscle. Can J Physiol Pharmacol 78:75-80.
276. Lee E and Lee C (1997) Clinical comparison of selective and non-selective alpha1A-adrenoceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. Br J Urol 80:606-611.
277. Lee TJ, Zhang W and Sarwinski S (2000) Presynaptic beta (2)-adrenoceptors mediate nicotine-induced Noergic neurogenic dilation in porcine basilar arteries. Am J Physiol 279:H808-H816.
278. Leech CJ and Faber JE (1996) Different α-adrenoceptor subtypes mediate constriction of arterioles and venules. Am J Physiol 270:H710-H722.
279. 1A-adrenoceptors in the human prostate. J Urol 154:2096-2099.
280. Lewis T (1929) Experiments relating to the peripheral mechanisms involved in spasmodic arrest of the circulation in fingers: a variety of Raynaud's disease. Heart 15:7-101.
281. Li P, Zou AP, Al-Kayed NS, Rusch NJ and Harder DR (1994) Guanine nucleotide-binding proteins in aortic smooth muscle from hypertensive rats. Hypertension 23:914-918.
282. 2-adrenergic receptor. Proc Natl Acad Sci USA 90:3665-3669.
283. 2-adrenoceptors in rabbit and rat brain cortex in the absence of autoinhibition. Naunyn-Schmiedeberg's Arch Pharmacol 340:639-647.
284. 2-autoreceptors in rat submaxillary gland and heart atrium. Br J Pharmacol 107:246-255.
285. Limbird LE (1988) Receptors linked to inhibition of adenylate cyclase: additional signaling mechanisms. FASEB J 2:2686-2695.
286. Lindblad LE, Ekenvall L, Etzell BM and Bevegard S (1989) Adrenoceptors in Raynaud's disease. J Cardiovasc Pharmacol 14:881-888.
287. 2-C10 homolog responsible for an interspecies variation in antagonist binding. Mol Pharmacol 42:16-27.
288. 2-adrenergic receptor subtypes b and c. Science (Wash DC) 273:803-805.
289. 2C-adrenoceptor homolog. Mol Pharmacol 48:48-55.
290. 1A-adrenergic receptor. J Biol Chem 266:6365-6369.
291. 2-adrenergic receptor subtype, the gene for which is located on chromosome 2. Proc Natl Acad Sci USA 87:5094-5098.
292. 3-adrenoceptors in obesity. J Clin Invest 95:1109-1116.
293. Low AM, Lu-Chao H, Wang YF, Brown RD, Kwan CY and Daniel EE (1998) Pharmacological and immunocytochemical characterization of subtypes of alpha-1 adrenoceptors in dog aorta. J Pharmacol Exp Ther 285:894-901.
294. 3-adrenergic receptor. J Clin Invest 95:923.
295. 2-adrenergic receptor-Src protein kinase complexes. Science (Wash DC) 283:655-661.
296. MacDonald A, McLean M, MacAuly L and Shaw AM (1999) Effects of propranolol and L-NAME on beta-adrenoceptor-mediated relaxation in rat carotid artery. J Auton Pharmacol 19:145-149.
297. 1-adrenoceptor ligand binding sites. J Pharmacol Exp Ther 294:434-443.
298. 2A subtype. Br J Pharmacol 121:1721-1729.
299. 2a-adrenergic receptor subtype. Science (Wash DC) 273:801-803.
300. 2-C10 adrenergic receptors expressed in rat-1 fibroblast can regulate both adeny-lylcyclase and phospholipase D-mediated hydrolysis of phosphatidylcholine by interacting with pertussis toxin-sensitive guanine nucleotide-binding proteins. J Biol Chem 267:2149-2156.
301. Magalhaes M, Wenning GK, Daniel SE and Quinn NP (1995) Autonomie dysfunction in pathologically confirmed multiple-system atrophy and idiopathic Parkinson's disease - a retrospective comparison. Acta Neurol Scand 91:98-102.
302. Majewski H (1983) Modulation of noradrenaline release through activation of presynaptic β-adrenoceptors. J Auton Pharmacol 3:47-60.
303. Majewski H, Hedler L and Starke K (1982) The noradrenaline release rate in the anaesthetized rabbit: facilitation by adrenaline. Naunyn-Schmiedeberg's Arch Pharmacol 321:20-27.
304. Majewski H, Rand MJ and Tung L-H (1981a) Activation of prejunctional β-adrenoceptors in rat atria by adrenaline applied exogenously or released as a cotransmitter. Br J Pharmacol 73:669-679.
305. Majewski H, Tung L-H and Rand MJ (1981b) Hypertension through adrenaline activation of prejunctional β-adrenoceptors. Clin Exp Pharmacol Physiol 8:463-468.
306. Makaritsis KP, Handy DE, Johns C, Kobilka B, Gravas I and Gravas H (1999) Role of alpha 2B-adrenergic receptors in the development of salt-induced hypertension. Hypertension 33:14-17.
307. Malik KU and Muscholl E (1969) Effect of sympathomimetic amines on the response of the perfused mesenteric artery preparation to adrenergic nerve stimulation. Arzneim-Forsch 19:1574-1579.
308. 3-adrenoceptors. Br J Pharmacol 117:943-949.
309. Man in't Veld AJ, Boomsma F, Moleman P and Schalekamp MADH (1987) Congenital dopamine-betahydroxylase deficiency, a novel orthostatic syndrome. Lancet 1:183-188.
310. 3-adrenoceptors and intestinal motility. Fundam Clin Pharmacol 9:332-342.
311. 3-selective antagonists, aryloxypropanolaminotetratine. Br J Pharmacol 117:1374-1376.
312. Maurice DH and Haslam RJ (1990) Nitroprusside enhances isoprenaline-induced increases in cAMP in rat aortic smooth muscle. Enr J Pharmacol 191:471-475.
313. McAdams RP and Waterfall JF (1986) The effect of age on the sensitivity of pre- and postsynaptic alpha-adrenoceptors to agonists and antagonists in the rat. Naunyn-Schmiedeberg's Arch Pharmacol 334:430-435.
314. McCafferty GP, Nadelsky DP and Hieble JP (1999) Characterization of postjunctional alpha-adrenoceptors in the pithed mouse. Gen Pharmacol 33:99-105.
315. McCulloch MW, Bevan JA and Su C (1975) Effects of phenoxybenzamine and norepinephrine on transmitter release in the pulmonary artery of the rabbit. Blood Vessels 12:122-133.
316. McGrath JC (1982) Evidence for more than one type of postjunctional α-adrenoceptor. Biochem Pharmacol 31:467-484.
317. McGrath JC, Lepor H and Wyllie MG (1996) Report of a unique meeting between the alpha-blocker subcommittee and the pharmacological industry. Urology 48:665-667.
318. 2B-adrenoceptor subtypes. Br J Pharmacol 98:890-897.
319. 1-adrenoceptor subtypes and in human prostate. J Auton Pharmacol 16:21-28.
320. 1-adrenoceptor subtypes. Naunyn-Schmiedeberg'ts Arch Pharmacol 352:1-10.
321. Michel MC, Mehlburger L, Bressel H-U, Schumacher H, Schäfers RF and Goepel M (1998a) Tamsulosin treatment of 19,395 patients with lower urinary tract symptoms: does co-morbidity alter tolerability? J Urol 160:784-791.
322. 1-Adrenoceptor subtypes in the human cardiovascular and urogenital systems. Adv Pharmacol 42:394-398.
323. Miller RJ (1998) Presynaptic receptors. Ann Rev Pharmacol Toxicol 38:201-227.
324. Miller JW, Hu ZW, Okazaki M, Fujinaga M and Hoffman BB (1996) Expression of alpha 1 adrenergic receptor subtype mRNAs in the rat cardiovascular system with aging. Mech Ageing Dev 87:75-89.
325. 2-adrenoceptors in canine pulmonary and systemic blood vessels. Eur J Pharmacol 118:123-129.
326. Milton AS, Carr GA, Luby CD, Scarlett JA, White R and Callingham BA (1999) Changes in reactivity of the digital artery of the fallow deer, Dama dama, in summer and winter. J Therm Biol 24:465-470.
327. 1-Adrenergic receptor subtypes, inositol phosphates and sources of cell calcium. Pharmacol. Rev 40:87-119.
328. Misu Y and Kubo T (1986) Presynaptic β-adrenoceptors. Med Res Rev 6:197-225.
329. Misu Y, Kuwahara M, Amano H and Kubo T (1989) Evidence for tonic activation of prejunctional β-adrenoceptors in guinea-pig pulmonary arteries by adrenaline derived from the adrenal medulla. Br J Pharmacol 98:45-50.
330. Misu Y, Kuwahara M, Goshima Y and Kubo T (1990) Stress-induced increases in adrenaline further activate tonically presynaptic β-adrenoceptors in renal arteries from prehypertensive rats of spontaneously hypertensive strain. Arch Int Pharmacodyn 305:100-110.
331. Miura M, Belvisi MG, Stritton CD, Yacoub MH and Barnes PJ (1992) Role of potassium channels in bronchodilator responses in human airways. Am Rev Respir Dis 148:132-136.
332. 3H)-CGP-12177, generally classified as an antagonist, is a thermogenic agonist in brown tissue. Biochem J 261:401-405.
333. 2-autoreceptors on the sympathetic nerves of human, rat and rabbit blood vessels. Fundam Clin Pharmacol 7:372.
334. Molenaar P, Malta E, Jones CR, Buxton BR and Summers RJ (1988) Autoradiographic localization and function of β-adrenoceptors on the human internal mammary artery and saphenous vein. Br J Pharmacol 95:225-233.
335. Moncada S, Palmer RMJ and Higgs EA (1991a) Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 43:109-142.
336. Moncada S, Rees DD, Schulz R and Palmer RMJ (1991b) Development and mechanism of a specific supersensitivity to nitrovasodilators after inhibition of vascular nitric oxide synthesis in vivo. Proc Natl Acad Sci USA 88:2166-2170.
337. Morris AD, Petrie JR and Connel JMC (1994) Insulin and hypertension. J Hypertens 12:633-642.
338. 3H-prazosin binding. Mol Pharmacol 29:321-333.
339. Motomura S, Zerkowski H-R, Daul A and Brodde O-E (1990) On the physiologic role of beta-2 adrenoceptors in the human heart: in vitro and in vivo studies. Am Heart J 119:608-619.
340. Moura D, Paiva MQ, Vaz-da-Silva MJ and Guimarães S (1997) Ontogenesis of beta-adrenoceptors and the adrenaline content of the adrenals. Pharmacol Toxicol 81:14.
341. 3H-noradrenaline in saphenous vein of neonate and adult dogs. Naunyn-Schmiedeberg's Arch Pharmacol 347:186-191.
342. Müller-Schweinitzer E (1984) Alpha-adrenoceptors, 5-hydroxytryptamine receptors and the action of dihydroergotamine in human venous preparations obtained during saphenectomy procedures for varicose veins. Naunyn-Schmiedeberg's Arch Pharmacol 327:299-303.
343. Muramatsu I, Murata S, Isaka M, Piao HL, Zhu J, Suzuki F, Miyamoto S, Oshita M, Watwnabe Y and Taniguchi T (1998) Alpha 1-adrenoceptor subtypes and two receptor systems in vascular tissues. Life Sci 62:1461-1465.
344. 1-adrenoceptors in vascular smooth muscle. Br J Pharmacol 99:197-201.
345. Murohara T, Yasue H, Ohgushi M, Sakaino N and Jougasaki M (1991) Age related attenuation of the endothelium dependent relaxation to noradrenaline in isolated pig coronary arteries. Cardiovasc Res 25:1002-1009.
346. Murphy TJ and Bylund DB (1988) Characterization of alpha-2 adrenergic receptors in OK cell, an opossum kidney cell line. J Pharmacol Exp Ther 244:571-578.
347. Nahorski SR, Barnett DB and Cheung Y-D (1985) α-Adrenoceptor-effector coupling: affinity states or heterogeneity of the a-adrenoceptor? Clin Sci 68:39s-42s.
348. Nedergaard OA and Abrahamsen J (1990) Modulation of noradrenaline release by activation of presynaptic β-adrenoceptors in the cardiovascular system. Ann NY Acad Sci 604:528-554.
349. Netten PM, de Vos K, Horstink MW and Hoefnagels WH (1995) Autonomie dysfunction in Parkinson's disease, tested with a computerized method using a Finapres device. Clin Auton Res 5:85-89.
350. 3-adrenergic receptor antagonist SR 59,230A. Mol Pharmacol 49:7-14.
351. 2-adrenoceptors and blood pressure regulation in the rat. Eur J Pharmacol 278:183-185.
352. 2-adrenoceptors in the dog saphenous vein. Naunyn-Schmiedeberg's Arch Pharmacol 348:264-268.
353. Nunes JP, Moura D, Guimarães S and De la Lande IS (1991) Postsynaptic α-adrenoceptors in the perfused canine saphenous vein in vitro. Pharmacol Res 23:409-414.
354. O'Donnell SR and Wanstall JC (1984) Beta-1 and beta-2 adrenoceptor-mediated responses in preparations of pulmonary artery and aorta from young and aged rats. J Pharmacol Exp Ther 228:733-738
355. 2-selective agonist procaterol of vascular and atrial preparations with different functional β-adrenoceptor populations. Br J Pharmacol 84:227-235.
356. O'Donnell SR and Wanstall JC (1986) Thyroxine treatment of aged or young rats demonstrates that vascular responses mediated by β-adrenoceptors subtypes can be differentially regulated. Br J Pharmacol 88:41-49.
357. Ohmi K, Shinoura H, Nakayama Y, Goda N and Tsujimoto G (1999) Characterization of alpha 1-adrenoceptors expressed in a novel vascular smooth muscle cell line cloned from p53 knockout mice, P53LMAC01 (AC01) cells. Br J Pharmacol 127:756-762.
358. 3-adrenergic functions. Naunyn-Schmiedeberg's Arch Pharmacol 361:134-145.
359. Oriowo MA (1994) Atypical beta-adrenoceptors in the rat isolated common carotid artery. Br J Pharmacol 113:699-702.
360. Oriowo MA (1995) Different atypical beta-adrenoceptors mediate isoprenaline-induced relaxation in vascular and non-vascular smooth muscles. Life Sci 56:PL269-PL275.
361. Oriowo MA, Hieble JP and Ruffolo RR Jr (1991) Evidence for heterogeneity of prejunctional alpha-2-adrenoceptors. Pharmacology 43:1-13.
362. Osswald W and Guimarães S (1983) Adrenergic mechanisms in blood vessels: morphological and pharmacological aspects. Rev Physiol Biochem Pharmacol 96:53-122.
363. 2A-autoreceptors in the canine saphenous vein. Naunyn-Schmiedeberg's Arch Pharmacol 356:368-373.
364. 2-adrenoceptors of the dog mesenteric and rat femoral veins. Naunyn-Schmiedeberg's Arch Pharmacol 360:165-170.
365. Paiva MQ, Moura D, Vaz-da-Silva MJ and Guimarães S (1994) Postnatal development of vascular β-adrenoceptor-mediated responses and the increase in the adrenaline content of the adrenal gland have a parallel course. Naunyn-Schmiedeberg's Arch Pharmacol 350:28-33.
366. Palmer RMJ, Ferrige AG and Moncada S (1987) Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature (Lond) 327:524-525.
367. Parent R, Al-Obaidi M and Lavallee M (1993) Nitric oxide formation contributes to β-adrenergic dilation of resistance coronary vessels in conscious dogs. Circ Res 73:241-251.
368. Pegram BL, Bevan RD and Bevan JA (1976) Facial vein of the rabbit: neurogenic vasodilation mediated by β-adrenergic receptors. Circ Res 39:854-860.
369. 2-adrenoceptors in the responses of proximal and distal segments of the canine saphenous vein to exogenous and endogenous noradrenaline. Naunyn-Schmiedeberg's Arch Pharmacol 343:616-622.
370. 1D-adrenergic receptor cDNA. Mol Pharmacol 40:876-883.
371. Piascik MT, Guarino RD, Smith MS, Soltis EE, Saussy DL and Perez DM (1995) The specific contribution of the novel alpha-1D adrenoceptor to the contraction of vascular smooth muscle. J Pharmacol Exp Ther 275:1583-1589.
372. Piascik MT, Hrometz SL, Edelman SE, Guarino RD, Hadley RW and Brown RD (1997) Immunocytochemical localization of the alpha-1E adrenergic receptor and the contribution of this and the other subtypes to vascular smooth muscle contraction: analysis with selective ligands and antisense oligonucleotides. J Pharmacol Exp Ther 283:854-868.
373. 1-Adrenoceptor subtypes and the regulation of peripheral hemodynamics in the conscious rat. Eur J Pharmacol 186:273-278.
374. Polónia J, Paiva MQ and Guimarães S (1985) Pharmacological characterization of postsynaptic a-adrenoceptor subtypes in five different dog arteries in vitro. J Pharm Pharmacol 37:205-208.
375. Powell CE and Slater IH (1958) Blocking of inhibitory adrenergic receptors by a dichloro analog of isoproterenol. J Pharmacol Exp Ther 122:480-488.
376. 3-adrenoceptor knockout mice: evidence for a new β-adrenergic receptor in brown adipose tissue. Br J Pharmacol 124:1684-1688.
377. 1 adrenergic receptor subtypes. J Urol 150:546-551.
378. 1a-adrenergic receptor subtype-selective antagonists. J Pharmacol Exp Ther 294:224-229.
379. Rea RF, Biaggioni I, Robertson RM, Haile V and Robertson D (1990) Reflex control of sympathetic nerve activity in dopamine-β-hydroxylase deficiency. Hypertension 156:107-112.
380. Rebich S, Devine JO and Armstead WM (1995) Role of nitric oxide and cAMP in β-adrenoceptor-induced pial artery vasodilation. Am J Physiol 268:H1071-H1076.
381. 2-adrenergic receptor subtype. Proc Natl Acad Sci USA 85:301-6305.
382. 3-adrenoceptor in the regulation of body composition. J Clin Invest 100:1098-1106.
383. Richard V, Tanner FC, Tschudi M and Luscher TF (1990) Different activation of L-arginine pathway by bradykinin, serotonin and clonidine in coronary arteries. Am J Physiol 259:H1433-H1439.
384. 125I)-cyanopindolol binding sites in rat soleus muscle. Br J Pharmacol 109:344-352.
385. 2 adrenoceptors. Acta Pharmacol 42:499-501.
386. 2-adrenergic receptors. J Biol Chem 274:16701-16708.
387. Rohrer DK, Desai KH, Jasper JR, Stevens ME, Regula DJ, Barsh GS, Bernstein D and Kobilka BK (1996) Targeted disruption of the mouse beta 1-adrenergic receptor gene: developmental and cardiovascular effects. Proc Natl Acad Sci USA 93:7375-7380.
388. Rohrer DK and Kobilka BK (1998) Insights from in vivo modification of adrenergic receptor gene expression. Ann Rev Pharmacol Toxicol 38:351-373.
389. 1-adrenergic receptor knockout mouse. Am J Physiol 274:H1184-H1193.
390. 3-adrenergic effect on lipolysis in human subcutaneous adipose tissue. J Clin Endocrinol Metab 77:352-355.
391. Ross G (1976) Adrenergic responses of the coronary vessels. Circ Res 39:461-465.
392. 1-adrenergic receptors by vessel bed and age. Circulation 100:2336-23443.
393. Ruffolo RR Jr and Hieble JP (1999) Adrenoceptor pharmacology: urogenital applications. Eur Urol 36:17-22.
394. Ruffolo RR, Nichols AJ, Stadel JM and Hieble JP (1991) Structure and function of o2-adrenoceptors. Pharmacol Rev 43:475-501.
395. 2-adrenoceptor subtypes. Ann Rev Pharmacol Toxicol 33: 243-279.
396. 2C-Adrenoceptor-modulated release of noradrenaline in human right atrium. Br J Pharmacol 116:2617-2624.
397. 2-adrenoceptors by isoprenaline and adrenaline enhances noradrenaline release in cortical kidney slices of young spontaneously hypertensive rats. Naunyn-Schmiedeberg's Arch Pharmacol 345:25-32.
398. 2-adrenoceptors in the blood vessels of the gracilis muscle of the dog. Circ Res 46:344-352.
399. 2-adrenoceptor activation in rat aortic rings. Br J Pharmacol 119:505-510.
400. Sakate N, Shibata M and Shibata S (1997) Endothelium- and cytochrome P-450-dependent relaxation induced by isoprenaline in rat aortic rings. Eur J Pharmacol 319:37-41.
401. Satake N, Zhou Q, Morikawa M, Inoue M and Shibata S (1995) Potentiating effect of nicorandil, an antianginal agent, on relaxation induced in isolated rat aorta: involvement of cGMP-inhibitable cAMP phosphodiesterase. J Cardiovasc Pharmacol 25:489-494.
402. 1-adrenoceptor subtypes in rabbit arteries. Eur J Pharmacol 350:67-73.
403. 1-adrenoceptor subtypes in rabbit aorta and arteries: regional difference and co-existence. Eur J Pharmacol 374:229-240.
404. 1-adrenoceptor mechanisms and inhibitory effects of isradipine. Arch Int Pharmacodyn Ther 330:190-205.
405. 1D-subtype. J Pharmacol Exp Ther 278:136-144.
406. 3H)-prazosin binding and contraction experiments. Eur J Pharmacol 246:275-281.
407. 1-adrenoceptor subtypes. Pharmacol Toxicol 83:23-25.
408. Schäfers RF, Poller U, Pönicke K, Geissler M, Daul AE, Michel MC and Brodde O-E (1997) Influence of adrenoceptor and muscarinic receptor blockade on the cardiovascular effects of exogenous noradrenaline and of endogenous noradrenaline released by infused tyramine. Naunyn-Schmiedeberg's Arch Pharmacol 355:239-249.
409. Schäfers RF, Nürnberger J, Herrmann B, Wenzel RR, Philipp T and Michel MC (1999) Adrenoceptors mediating the cardiovascular and metabolic effects of α-methylnoradrenaline in humans. J Pharmacol Exp Ther 289:918-925.
410. B-adrenoceptor subtypes in the pithed rat. J Auton Pharmacol 12:125-136.
411. 1-adrenergic receptors in human tissues. Adv Pharmacol 42:390-394.
412. 1-adrenergic receptor subtype. J Biol Chem 265:8183-8189.
413. Shafiei M and Mahmoudian M (1999) Atypical β-adrenoceptors of rat thoracic aorta. Gen Pharmacol 32:557-562.
414. 3-adrenergic receptor cardiovascular regulation in conscious primates, rats and dogs. J Pharmacol Exp Ther 278:1435-1443.
415. 3-adrenoceptor-induced peripheral vasodilation in conscious dogs. Clin Res 41:348A.
416. Shen Y-T, Zhang H and Vatner SF (1994) Peripheral vascular effects of beta-3 adrenergic receptor stimulation in conscious dogs. J Pharmacol Exp Ther 268:466-473.
417. Shi AG, Kwan CY and Daniel EE (1989) Relation between density (maximum binding) and alpha adrenoceptor binding sites and contractile response in four canine vascular tissues. J Pharmacol Exp Ther 250:1119-1124.
418. Shoji T, Tsuru H and Shigei T (1983) A regional difference in the distribution of postsynaptic alpha-adrenoceptor subtypes in canine veins. Naunyn-Schmiedeberg's Arch Pharmacol 324:246-255.
419. Siwik DA and Brown RD (1996) Regulation of protein synthesis by alpha 1-adrenergic receptor subtypes in cultured rabbit aortic vascular smooth muscle cells. J Cardiovasc Pharmacol 27:508-518.
420. 1- and β-adrenoceptors in relation to sympathetic nerve endings in failing human myocardium. Naunyn-Schmiedeberg's Arch Pharmacol 358:R633.
421. Skrbic R and Chiba S (1992) Pharmacological properties of alpha 1-adrenoceptor-mediated vasoconstrictions in dog and monkey lingual arteries: evidence for subtypes of alpha 1-adrenoceptors. Heart Vessels 7:82-90.
422. 1-adrenoceptor subtypes mediating vasoconstriction in rabbit cutaneous resistance arteries. Br J Pharmacol 122:825-832.
423. Sooch S and Marshall I (1995) An atypical β-adrenoceptor mediates relaxation of the rat isolated mesenteric artery. Br J Pharmacol 114:22P.
424. Sooch S and Marshall I (1996) Evidence for atypical β-adrenoceptors in rat vasculature. Br J Pharmacol 117:261P.
425. Sooch S and Marshall (1997; Atypical β-adrenoceptors in the rat vasculature. Ann N Y Acad Sci USA 812:211-212.
426. 1L-adrenoceptor pharmacology in rat small mesenteric artery. Br J Pharmacol 127:661-670.
427. Starke K (1972) Alpha sympathomimetic inhibition of adrenergic and cholinergic transmission in the rabbit heart. Naunyn-Schmiedeberg's Arch Pharmacol.274:18-45.
428. Starke K (1977) Regulation of noradrenaline release by presynaptic receptor systems. Rev Physiol Biochem Pharmacol 77:1-124.
429. Starke K (1981) α-Adrenoceptor subclassification. Rev Physiol Biochem Pharmacol 88:199-236.
430. Starke K (1987) Presynaptic α-autoreceptors. Rev Physiol Biochem Pharmacol 107:73-146.
431. Starke K, Borowski E and Endo T (1975a) Preferential blockade of presynaptic α-adrenoceptors by yohimbine. Eur J Pharmacol 34:385-388.
432. Starke K and Endo T (1975) Presynaptic α-adrenoceptors. Gen Pharmacol 7:307-312.
433. Starke K, Endo T and Taube HD (1975b) Relative pre- and postsynaptic potencies of α-adrenoceptor agonists in the rabbit pulmonary artery. Naunyn-Schmiedeberg's Arch Pharmacol 291:55-78.
434. Starke K, Montel H, Gayk W and Merker R (1974) Comparison of the effect of clonidine on pre- and postsynaptic adrenoceptor in the rabbit pulmonary artery. Naunyn-Schmiedeberg's Arch Pharmacol 285:133-150.
435. 2-adrenoceptors: subtype determination. Pharmacol Commun 6:99-108.
436. 1-Adrenoceptor subtypes in rat aorta and mesenteric small arteries are preserved during left ventricular dysfunction post-myocardial infarction. Cardiovasc Res 33:706-713.
437. Stein CM, Nelson R, Huai B, Wood M and Wood AJJ (1997) Norepinephrine release in the human forearm: effects of epinephrine. Hypertension 30:1078-1084.
438. Steinberg SF, Jaffe EA and Bilezikian JP (1984) Endothelial cells contain beta adrenoceptors. Naunyn-Schmiedeberg's Arch Pharmacol 325:310-313.
439. Stevens MJ, Rittinghausen RE, Medcalf RL and Moulds RFW (1982) Prejunctional β-adrenoceptors in human digital arteries. Eur J Pharmacol 83:263-270.
440. Stjärne L and Brundin J (1975) Dual adrenoceptor-mediated control of noradrenaline secretion from human vasoconstrictor nerves: facilitation by β-receptors and inhibition by a-receptors. Acta Physiol Scand 94:139-141.
441. 3-adrenoceptor. Ann Rev Pharmacol Toxicol 37:421-450.
442. Strosberg AD, Gerhardt CC, Gros J, Jockers R and Pietri-Rouxel F (1998) Reply on the putative existence of a fourth β-adrenoceptor: proof is still missing. Trends Pharmacol Sci 19:165-166.
443. Strosberg AD and Pietri-Rouxel F (1996) Function and regulation of the three β-adrenoceptor. Trends Pharmacol Sci 17:373-381.
444. Summers RJ, Kompa A and Roberts SJ (1997) β-Adrenoceptor subtypes and their desensitization mechanisms. J Auton Pharmacol 17:331-343.
445. 2-adrenoceptor that blocks coupling to potassium but not calcium currents. Science (Wash DC) 257:977-980.
446. 3-adrenergic receptor gene. J Biol Chem 270:29483-294922.
447. Tagaya E, Tamaoki J, Takemura H, Isono K and Nagai A (1999) Atypical adrenoceptor-mediated relaxation of canine pulmonary artery through a cyclic adenosine monophosphate-dependent pathway. Lung 177:321-332.
448. Taira N, Yabuuchi Y and Yamashita S (1977) Profile of β-adrenoceptors in femoral, superior mesenteric and renal vascular beds of dogs. Br J Pharmacol 59:577-583.
449. Takahashi H, Yoshida T, Nishimura N, Nakanishi T, Hondo M and Yoshimura M (1992) Beta3-adrenergic agonist, BRL-2S830A, and alpha/beta blocker, arotinolol, markedly increase regional blood flow in the brown tissue in anesthetized rats. Jap Circ J 56:936-942.
450. 1-adrenoceptor mechanisms for phenylephrine and tizanidine in rabbit thoracic aorta and common iliac artery. Can J Physiol Pharmacol 49:1819-1824.
451. Tamaoki J, Tagaya E, Isono K and Nagai A (1998) Atypical adrenoceptor-mediated relaxation of canine pulmonary artery through a cAMP-dependent pathway. Biochem Biophys Res Comm 248:722-727.
452. 1A-adrenoceptor agonist NS-49 on guinea pig nasal mucosa vasculature. Eur J Pharmacol 387:73-78.
453. 2-adrenoceptor-mediated control mechanism in the pithed rat. Naunyn-Schmiedeberg's Arch Pharmacol 349:570-577.
454. Tarizzo V and Dahlöf C (1989) Adrenaline-induced enhancement of the blood pressure response to sympathetic nerve stimulation in adrenal demedullated pithed rat. Naunyn-Schmiedeberg's Arch Pharmacol 340:144-150.
455. Tavernier G, Galitzky J, Bousquet-Melou A, Montrastruc JL and Berlan M (1992) The positive chronotropic effect induced by BRL 37344 and CGP 12177, two beta-3 adrenergic agonists, does not involve cardiac beta adrenoceptors but baroreflex mechanisms. J Pharmacol Exp Ther 263:1083-1090.
456. Teixeira F (1977) The effect of drugs and denervation on removal and accumulation of adrenaline in the perfused hind-limb of the dog. Arch Int Pharmacodyn Ther 225:221-231.
457. 3-adrenoceptor agonist. Br J Pharmacol 112:55-58.
458. 1d-adrenoceptor subtype is involved in the noradrenaline-induced contractions of rat aorta. Life Sci 57:PL159-PL163.
459. Theroux TL, Esbenshade TA, Peavy RD and Minneman KP (1996) Coupling efficiencies of human alpha 1-adrenergic receptor subtypes: titration of receptor density and responsiveness with inducible and repressible expression vectors. Mol Pharmacol 50:1376-1387.
460. 2 mechanisms in vivo and in vitro. Clin Sci 68:147s-150s.
461. Thompson JM, Wallin BG, Lambert GW, Jennings GL and Esler MD (1998) Human muscle sympathetic activity and cardiac catecholamine spillover: no support for augmented sympathetic noradrenaline release by adrenaline co-transmission. Clin Sci 94:383-393.
462. 2-adrenoceptor contributes to cerebral vasorelaxation. Hypertension 30:830-836.
463. 2-Adrenoceptors: classification, localization, mechanisms and target for drugs. J Med Chem 25:1389-1401.
464. Toda N (1983) Alpha adrenergic receptor subtypes in human, monkey and dog cerebral arteries. J Pharmacol Exp Ther 226:861-868.
465. Toda N and Shimizu I (1987) Neuroeffector function in mesenteric arteries isolated from beagles of different ages. J Pharmacol Exp Ther 240:223-227.
466. Toda N, Yoshida K and Okamura T (1995) Involvement of nitroxidergic and noradrenergic nerves in the relaxation of dog and monkey temporal veins. J Cardiovasc Pharmacol 25:741-747.
467. 3-adrenergic-receptor gene polymorphism with essential hypertension in the Sardinian population, J Hypertens 17:33-38.
468. Toyoshima H, Nasa Y, Hashizume Y, Koseki Y, Isayama Y, Kohsaka Y, Yamada T and Takeo S (1998) Modulation of cAMP-mediated vasorelaxation by endothelial nitric oxide and basal cGMP in vascular smooth muscle. J Cardiovasc Pharmacol 32:543-551.
469. 2A/D-adrenoceptor-deficient mice. Naunyn-Schmiedeberg's Arch Pharmacol 360:540-551.
470. 2C-subtype mediate inhibition of norepinephrine release in human kidney cortex. Mol Pharmacol 45:1168-1176.
471. 2 autoreceptors in pig brain are alpha-2A. J Pharmacol Exp Ther 278:462-467.
472. 2-autoreceptors: rat vena cava, rat atria, human kidney and guinea-pig urethra. Naunyn-Schmiedeberg's Arch Pharmacol 358:721-737.
473. Trochu J-N, Leblais V, Rautureau Y, Bévérelli F, Le Marec H, Bordeaux A and Gauthier C (1999) Beta 3-adrenoceptor stimulation induces vasorelaxation mediated essentially by endothelium-derived nitric oxide in rat thoracia aorta. Br J Pharmacol 128:69-76.
474. 2-adrenoceptors in the cardiovascular effects of moxonidine. Eur J Pharmacol 282:19-28.
475. 1-adrenoceptors in rabbit lower urinary tract and mesenteric artery. Eur J Pharmacol 327:25-32.
476. 1-adrenoceptor antagonists in rat aorta. Br J Pharmacol 118:299-310.
477. 1-adrenoceptor antagonists on noradrenaline-mediated contraction of rat small mesenteric artery. Br J Pharmacol 118:1308-1316.
478. Van der Zypp A, Kang K-B and Majewski H (2000) Age-related involvement of the endothelium in β-adrenoceptor-mediated relaxation of rat aorta. Eur J Pharmacol 397:129-138.
479. Vanhoutte PM (1980) Physical factors and regulation of vascular smooth muscle function, in Handbook of Physiology, Section 2: Circulation, volume II: Vascular Smooth Muscle (Bohr DF, Somlyo AP, Sparks HV eds) pp 443-474, The American Physiological Society, Washington, DC.
480. Vanhoutte PM (2000) Are there functional endothelial adrenoceptors? Pharmacol Toxicol 87:L3.
481. Vanhoutte PM and Lorenz RR (1970) Effect of temperature on the reactivity of saphenous, mesenteric, and femoral veins of the dog. Am J Physiol 218:1746-1750.
482. 2-adrenoceptors and endothelium-derived relaxing factor. Am J Med 87:1S-5S.
483. VanRipper DA and Bevan JA (1991) Selective variation of agonist and neuronally mediated vasoconstriction with middle cerebral artery branch order. J Pharmacol Exp Ther 257:879-886.
484. Vargas HM Zhou L and German AJ (1994) Role of vascular alpha-1 adrenoceptor subtypes in the pressor response to sympathetic nerve stimulation in the pithed rat. J Pharmacol Exp Ther 271:748-754.
485. Vatner SF, Knight DR and Hintze TH (1985) Norepinephrine-induced beta 1-adrenergic peripheral vasodilation in conscious dogs. Am J Physiol 249:H49-H56.
486. Vaz-da-Silva MJ, Magina S, Domingues-Costa A, Moura D and Guimarães S (1996) The role of the endocardium in the facilitatory effect of bradykinin on electrically-induced release of noradrenaline in rat cardiac ventricle. Br J Pharmacol 118: 364-368.
487. 2+ channels in rat portal vein myocites. Br J Pharmacol 129:1497-1505.
488. Vila E and Badia A (1995) Chronic administration of oxprenolol and metoprolol attenuated sympathetic cardivascular responses in non-adrenalectomized pithed rats. J Autan Pharmacol 15:393-402.
489. Villalobos-Molina R and Ibarra M (1996) Alpha 1-adrenoceptors mediating contraction in arteries of normotensive and spontaneously hypertensive rats are of the alpha 1D or alpha 1A subtypes. Eur J Pharmacol 298:257-263.
490. 1D-adrenoceptor in the vasculature of young and adult spontaneously hypertensive rats. Br J Pharmacol 126:1534-1536.
491. Vincent HH, Man in't Veld AJ, Boomsma F, Wenting GS and Schalekamp MADH (1982) Elevated plasma noradrenaline in response to β-adrenoceptor stimulation in man. Br J Clin Pharmacol 13:717-721.
492. Vizi ES, Somogyi GT, Hadhazy P and Knoll J (1973) Effect of duration and frequency of stimulation on the presynaptic inhibition by α-adrenoceptor stimulation of the adrenergic transmission. Naunyn-Schmiedeberg's Arch Pharmacol 280:79-91.
493. 3-adrenergic-receptor gene. N Engl J Med 333:343-347.
494. Wanstall JC and O'Donnell SR (1989) Influence of age on calcium entry blocking drugs in rat aorta spasmogen-dependent. Eur J Pharmacol 159:241-246.
495. Waterman SA (1997) Role of N-, P- and Q-type voltage-gated calcium channels in transmitter release from sympathetic neurones in the mouse isolated vas deferens. Br J Pharmacol 120:393-398.
496. Watkins PJ (1998) The enigma of autonomic failure in diabetes. J R Coll Physicians Lond 32:360-365.
497. 2B-adrenergic receptor. Mol Pharmacol 38:681-688.
498. White RE, Jolly SR and Carrier GO (1986) Enhanced relaxation of canine coronary artery to isoproterenol and salbutamol after removal of endothelial cells. Gen Pharmacol 17:497-499.
499. 3-adrenergic-receptor gene with features of the insulin resistance syndrome in Finns. N Engl J Med 333:348-351.
500. Willette RN, Hieble JP and Sauermelch CF (1991) The role of alpha adrenoceptor subtypes in sympathetic control of the acral-cutaneous microcirculation. J Pharmacol Exp Ther 256:599-605.
501. 1A-adrenoceptor selective antagonists. Br J Pharmacol 127:252-258.
502. Wilson C, Wilson S, Piercy V, Sennitt MV and Arch S Jr (1984) The rat lipolytic beta-adrenoceptor studies using novel beta-adrenoceptor agonists. Eur J Pharmacol 100:309-319.
503. Wilson S, Chambers JK, Park JE, Ladurner A, Cronk DW, Chapman CG, Kallender H, Browne MJ, Murphy J and Young PW (1996) Agonist potency of the cloned human beta-3 adrenoceptor depends on receptor expression level and nature of assay. J Pharmacol Exp Ther 279:214-221.
504. 2B-Adrenoceptor mRNA expression during rat brain development. Dev Brain Res 100:90-100.
505. 2A Messenger RNA expression. Neuroscience 76:241-260.
506. 3H) rauwolscine binding. Neuroscience 76:261-272.
507. 2A-adrenoceptor with multiple Gi-family proteins: studies with pertussis toxin-resistant G-protein mutants. Biochem J 321:721-728.
508. Wu D, Katz A, Lee CH and Simon MI (1992) Activation of phospholipase C by alpha 1-adrenergic receptors is mediated by the alpha subunits of Gq family. J Biol Chem 267:25798-25802.
509. Xiao RP, Ji X and Lakatta EG (1995) Functional coupling of beta 2-adrenoceptor to a pertussis toxin-sensitive G protein in cardiac myocytes. Mol Pharmacol 47:322-329.
510. 1-adrenoceptor subtypes in aortas of 12-month-old spontaneously hypertensive rats. Eur J Pharmacol 344:31-36.
511. 1-adrenoceptor subtypes with maturation and ageing in different rat blood vessels. Clin Exp Pharmacol Physiol 24:415-417.
512. Yamaguchi I and Kopin IJ (1980) Differential inhibition of alpha-1 and alpha-2 adrenoceptor mediated pressor responses in pithed rats. J Pharmacol Exp Ther 214:275-281.
513. Yamamoto Y and Koike K (1999) Alpha1-adrenoceptors in the guinea pig thoracic aorta. J Smooth Muscle Res 35:181-192.
514. Yan M, Zhang Y, Du XJ and Han C (1998) Functional assessment of alpha 1-adrenoceptor subtypes in porcine coronary artery. Clin Exp Pharmacol Physiol 25:682-685.
515. 1-adrenoceptor subtypes. Naunyn-Schmiedeberg's Arch Pharmacol 359:439-446.
516. Yousif M, Kadavil EA and Oriowo MA (1998) Heterogeneity of alpha 1-adrenoceptor subtypes mediating noradrenaline-induced contraction of the rat superior mesenteric artery. Pharmacology 56:196-206.
517. 3-adrenoceptor"? Trends Pharmacol Sci 11:3-7.
518. Zeiders JL, Seidler FJ and Slotkin TA (1999) Agonist-induced sensitization of β-adrenoceptor signaling in neonatal rat heart: expression and catalytic activity of adenylyl cyclase. J Pharmacol Exp Ther 291:503-510.
519. Zeiders JL, Seidler FJ and Slotkin TA (2000) Ontogeny of G-protein expression: control by beta-adrenoceptors. Brain Res Dev Brain Res 120:125-134.
520. Zhang W, Edvinsson L and Lee TJ-F (1998) Mechanism of nicotine-induced relaxation in the porcine basilar artery. J Pharmacol Exp Ther 284:790-797.
521. 1-Adrenoceptor subtypes. Eur J Pharmacol 375:261-276.
522. 1D-adrenoceptors have a role in the pressor response to phenylephrine in the pithed rat. Eur J Pharmacol 305:173-176.
523. Zoukos Y, Thomaides T, Mathias CJ and Cuzner ML (1999) High beta-adrenoceptor density on peripheral blood mononuclear cells in progressive multiple sclerosis: a manifestation of autonomic dysfunction. Acta Neurol Scand 99:1706-1712.
524. 1B-adrenergic receptor causes apoptotic neurodegeneration: multiple system atrophy. Nature Med 6:1388-1394.